At a glance
McMaster Innovation Park
Integrated Project Delivery (IPD)
OmniaBio B is a groundbreaking commercial-scale cell and gene therapy manufacturing facility, intended to advance life sciences and pioneering medicine to cure diseases such as cancer, cardiovascular, diabetes, and more.
The OmniaBio B ultra fast-tracked project is accommodating the largest cell and gene therapy Contract Development & Manufacturing Organization (CDMO) in Canada producing gene-modified and viral vectors in Hamilton, Ontario.
Executed under the innovative Integrated Project Delivery (IPD) method, this project showcases an on-time and on-budget project delivery, providing the core and shell infrastructure for accessibility to MIP and its partners, OmniaBio. The project will span 119,000 square feet over three storeys. Its final design will feature clean rooms, specialized labs, offices and Current Good Manufacturing Practice (cGMP) compliant manufacturing. Multiplex focused on driving a sustainable design at MIP including low energy, quality building with high performance. This included evaluating for LEED certification.
It is a core development in McMaster Innovation Park‘s $2 billion master plan development.
The project was completed on schedule in November 2023.
Project in numbers